NCT04826432

Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis

Efficacy and Feasibility of Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis - a Phase II Randomized Multicentric Trial

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To assess the efficacy of pasireotide in the reduction of clinically relevant postoperative digestive leakage after CRS plus HIPEC compared to placebo

Conditions

• Peritoneal Carcinomatosis

Interventions

Type	Name	Description
DRUG	Pasireotide 0.9 MG/ML	0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours
OTHER	Saline water	0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours

Timeline

• Start date: 2020-09-03
• Primary completion: 2024-02-07
• Completion: 2024-02-07
• First posted: 2021-04-01
• Last updated: 2024-02-08

Locations

1 site across 1 country: France